Path Fertility and its partners presented advancements in innovative fertility research at the American Society of Reproductive Medicine’s annual Congress & Expo. The 2024 conference brought together leading experts in the field to present the latest advancements in reproductive medicine and infertility. The presentations showcased new data and research in the following areas:
Economic Benefit of an Epigenetic Male Infertility Assessment
Presented by: Kristin Brogaard
Additional Authors: Lorry Schneider, Andy Olson
Published in Fertility and Sterility
Dr. Kristin Brogaard, co-founder and Chief Scientific Officer of Path Fertility, presented data for the economic utility of SpermQT. A more comprehensive assessment of male fertility with the epigenetic Sperm Quality Test (SpermQT) in the initial diagnostic workup shows cost and time savings for the patients, increased clinic margins, and significant cost savings for fertility benefits providers.
A Prospective Observational Trial of SpermQT Preliminary Results
Presented by: Dana Siegel
Additional Authors: Kristin Brogaard, Lorry Schneider, Alice Domar, Denny Sakkas, Kathleen Devine, Cassandra Roeca
Published in Fertility & Sterility
Dr. Dana Siegel, Clinical Fellow at Shady Grove Fertility, presented preliminary results from the SpermQT Prospective Observational Trial (“SPOT Study”). Early data from this prospective study suggest that despite having a higher TMC, men with an abnormal SpermQT result have fewer pregnancies after IUI than those with a normal score.
AlphaSperm Supplement Induced Epigenetic Reprogramming in Sperm
Presented by: Seth Parks
Additional Authors: Ryan Miller, Lily Millar, Kristin Brogaard, Paul Turek, Tim Jenkins
Published in Fertility and Sterility
We teamed up with AlphaSperm to investigate how the AlphaSperm supplement might impact sperm DNA methylation, and potentially affect fertility. The analysis provides strong evidence that sperm DNA methylation can be altered at biologically significant loci by supplementation with AlphaSperm.
Future advancements
These presentations demonstrate our focus on innovative, non-invasive diagnostics for the evolving needs in reproductive healthcare. Future advancements will further demonstrate the clinical and economic utility of the innovative products we develop in the coming years.
Path Fertility, is setting new standards in male fertility research and product development with a mission to raise the standard of care in reproductive health.
